
1. arch immunol ther exp (warsz). 2019 apr;67(2):79-88. doi:
10.1007/s00005-018-0532-8. epub 2018 nov 15.

modulation immune system chronic hepatitis c antiviral
interferon-free therapy.

urbanowicz a(1), zagożdżon r(1)(2)(3), ciszek m(4).

author information: 
(1)department immunology, transplant medicine internal diseases, medical
university warsaw, warsaw, poland.
(2)department clinical immunology, medical university warsaw, warsaw,
poland.
(3)institute biochemistry biophysics, polish academy sciences, warsaw, 
poland.
(4)department immunology, transplant medicine internal diseases, medical
university warsaw, warsaw, poland. mciszek@onet.pl.

the treatment patients chronic hepatitis c virus (hcv) infection has
changed tremendously past 2 years, increasing variety of
all-oral direct-acting antiviral (daa) treatment regimens available different
hcv genotypes distinct clinical settings. treatments significantly
improved safety patients advanced liver disease compared interferon 
(ifn)-based regimens. hcv modifies human immune system escape
immunosurveillance via several mechanisms. one basic mechanisms hcv 
the ability "switch" immune response reducing activity cells
responsible elimination virus-infected cells. ifn-free daa treatment
regimens provide unique opportunity assess effect hcv elimination 
the immune system. abrupt changes immune system cases be
responsible two alarming processes: viral reactivation patients with
chronic hepatitis b recurrence hepatocellular carcinoma patients with
previous successful cancer treatment.

doi: 10.1007/s00005-018-0532-8 
pmcid: pmc6420452
pmid: 30443787  [indexed medline]

